Please assess the completion status of the following clinical trial:

Trial Title: Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for cohort 1:~* Aged 18 years or over~* Moderate-to-severe UC, defined as:~SCCAI \> 5 and, i. A raised fecal calprotectin (\> 59 μg/g) or, ii. A raised CRP (\> 5 mg/L) or, iii. Endoscopic disease activity Mayo 2 or above, Evaluated within 4 weeks of study enrollment~* Commencing golimumab treatment~* Written informed consent to participate~* Sufficient English language skills to understand the patient information sheet and consent form~Inclusion Criteria for cohort 2:~* Aged 18 years or over~* Receiving golimumab treatment for UC for over 18 weeks (6 injections)~* Written informed consent to participate~* Sufficient English language skills to understand the patient information sheet and consent form~Exclusion Criteria (cohort 1 only):~* Contra-indication to golimumab: tuberculosis or severe infections~* Imminent need for colectomy (i.e. colectomy is being planned)~* Previous primary non-response to anti-TNF therapy in the opinion of the investigator~* Previous treatment with more than one anti-TNF therapy (excluding golimumab)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction cohort (Type: OTHER): Golimumab induction therapy
- Maintenance cohort (Type: OTHER): Golimumab maintenance therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).